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Background. Mucopolysaccharide polysulphate (MPS) has been used in medicine as an anti-inﬂammatory and antithrombotic
agent for over 50years. Its chemical structure permits considerable hydrogen bonding with adjacent water molecules, which
eﬀectively leads to hydration of the surrounding tissue. In addition, it stimulates endogenous hyaluronate synthesis, resulting
in an increase in water-binding capacity and viscoelasticity of the skin. Objective.T os t u d yt h ee ﬃcacy of 0.1% MPS on hydration
and elasticity of human skin. Methods. The ﬁrst part of this study was a randomized double blind placebo-controlled study which
included 60 female volunteers aged 30–45years with dry skin, deﬁned by Corneometer CM 825. The volunteers were treated with
either 0.1% MPS or vehicle control. All subjects were asked to apply 1g of cream to their face twice daily for a total period of 4
weeks. Skin hydration and elasticity were measured at baseline and week 4 with Corneometer CM 825 and cutometer MPA 580,
respectively, at forehead and both cheeks. The second part of this study focused on the eﬃcacy of 0.1% MPS on skin hydration
after single application. 20 female volunteers aged 30–45years with dry skin, deﬁned by Corneometer CM 825, were recruited to
the study. All subjects were asked to apply 2g of 0.1% MPS cream on entirely randomly selected forearm. Skin hydration at the
middle of both forearms was measured at baseline, immediately after application, and every 1hour after application for a period of
10hours. Results. 57 subjects (28 in vehicle control group, 29 in MPS) completed treatment protocol. The baseline skin hydration
of both groups was not signiﬁcantly diﬀerent (P = 0.47). Hower, there was a statistically signiﬁcant diﬀerence in skin hydration at
4 weeks between MPS and placebo group (P = 0.01). Skin elasticity was signiﬁcantly improved at week 4 in both groups (vehicle-
control, P<0.01, and MPS, P<0.01). However, no signiﬁcant diﬀerence in skin elasticity between MPS and vehicle-control
group was noted (P = 0.15). Lastly, there was a statistically signiﬁcant improvement in skin hydration after a single application
(P<0.01). This improvement was maintained for 10hours. Conclusions. MPS provided improvement of skin hydration but not
skin elasticity in woman with dry skin, compared with vehicle control. And MPS improved the skin hydration for at least 10hours
after single application.
1.Introduction
Characteristics of cutaneous aging include atrophy of the
dermis due to loss of collagen, degeneration of the elastic
ﬁber network, and loss of hydration of epidermis [1].
The severity of dry skin increases with aging. Additionally,
dry skin or xerosis is associated with age-independent
molecular changes including epidermal expression of basal
and diﬀerentiation-related keratins as well as premature
expression of the corniﬁed envelope protein, involucrin [2].
Mucopolysaccharide polysulphate (MPS), a naturally
occurring organoheparinoid compound, has been used
in medicine for over 50 years as an anti-inﬂammatory
and antithrombotic agent for the treatment of numerous
conditions, including osteoarthritis, thrombophlebitis, and
forthromboembolismprophylaxis[3–11].Skinpermeability
of MPS has been demonstrated by the achievement of
therapeutic systemic eﬀects, including prevention and treat-
ment of local symptoms associated with peripheral vascular
disorders, following topical administration [4].
Structurally speaking, MPSs are comprised of long
unbranched polysaccharides with repeating disaccharide
units. The chemical structure permits considerable hydrogen2 Dermatology Research and Practice
bonding with adjacent water molecules, which eﬀectively
leads to hydration of the surrounding tissue through its
water retention property [12–14]. In addition, MPS has
been shown to increase hydration by stimulating endoge-
nous hyaluronate synthesis, leading to increments in water-
binding capacity and viscoelasticity of the skin [14]. MPS
can decrease premature aging by inhibiting skin-degrading
enzymes, including elastase and hyaluronidase, and increase
RNA levels of important extracellular matrix molecules,
including glycosaminoglycans and proteoglycans [7].
The purpose of this study was to quantitatively assess the
eﬃcacy of 0.1% MPS on hydration and elasticity of human
skin.
2.MaterialandMethods
We conducted a randomized double blind placebo-con-
trolled study to determine if a measurable clinical eﬀect on
skin hydration and/or elasticity was achieved following the
application of an 0.1% MPS-containing cream (Hirudoid
mild cream, OLIC (Thailand), Ltd., Thailand). This study
was divided into 2 parts.
The ﬁrst part was designed to study the eﬃcacy of 0.1%
MPS on hydration and elasticity of human skin. 60 Thai
females between the ages of 30 and 45 were recruited for this
part of the study. Participants were selected from individuals
who responded to a posted announcement at the university
hospital aﬃliated with this study. Respondents were selected
to participate if they satisﬁed the following criteria: nondis-
eased facial skin, as conﬁrmed the investigators; dry skin
condition, deﬁned by the Corneometer CM825 (Courage-
Khazaka, Koln, Germany) reading of 60 or less; agreed to
undergo a “washout period” of one month in which no
topical medical treatment was allowed to apply to the face
and no systemic treatment known to aﬀect the skin could
be taken; the following agreed to adhere to the entire study
protocol. Exclusion criteria included: inability to provide
informed consent; diseased facial skin normal skin hydration
deﬁned by the Corneometer CM825 reading of more than
60 inability to undergo the washout period or inability to
adhere to the study protocol. Written informed consent was
obtained from each participant.
All volunteers with conﬁrmed dry skin (Corneometer
value ≤ 60) were randomized to 2 separate study groups
for application of either an 0.1% MPS-containing cream
or an MPS-free cream base as a vehiclecontrol twice daily
for four weeks. Skin hydration and elasticity were measured
at baseline and week 4 with corneometer CM 825 and
Cutometer MPA 580 (Courage-Khazaka, Koln, Germany),
respectively, at forehead and both cheeks.
During the 4-week study period, the application of
moisturizer, toner, foundation, concomitant medication, or
topical treatment of any type was prohibited at the study
drug treatment site. Only the use of the supplied cleanser
(Cetaphil gentle skin cleanser, Galderma Laboratories, L.P.,
USA) was permitted. Sixty grams per volunteer of either
MPS-containing or vehicle-control cream was given to
volunteers. Vehicle-control cream was composed of mineral
oil glycerin, emulgator, puriﬁed water, and liquid paraﬃn.
These two types of topical treatments were in identical
packaging, so that neither the volunteer nor the investigator
knew which type of treatment was being administered.
Volunteers were instructed to apply approximately 1 gram of
the study cream all over their faces, avoiding the periorbital
area, 2 times daily at morning and night after facial cleansing
for 28 days. Volunteers were instructed to rinse eyes with tap
water if any cream accidently entered the eyes.
Measurements of skin hydration and elasticity were
obtained at baseline and then immediately after the 4-week
period at forehead and both cheeks by two blinded investi-
gators. The hydration value (obtained by the corneometer
probe) was graded on a value in arbitrary units from 0 to
130 (for facial skin: 0–<50, very dry; 50–60, dry, and >60,
suﬃciently moistured). The elasticity value was obtained
by using the Cutometer probe. The result was presented in
10 diﬀerent values (R0–R9). The value of R5 reﬂects the
elasticity of the skin. All of the measurements were measured
in the temperature- and humidity-controlled room with
temperature of 25◦C and humidity of 60%.
T h es e c o n dp a r to ft h i ss t u d yw a sd e s i g n e dt os t u d y
the eﬃcacy of 0.1% MPS (Hirudoid mild cream, OLIC
(Thailand), Ltd., Thailand) on skin hydration after single
application. We conducted a randomized double blind
placebo-controlled study by recruiting 20 female volunteers
aged 30–45 years with dry skin, deﬁned by corneometer CM
825 (Courage-Khazaka, Koln, Germany). All subjects were
asked to apply 2g of 0.1% MPS cream on entirely randomly
selected volar forearm. Skin hydration at the middle of
both volar forearms was measured at baseline, immediately
after application, and every 1 hour after application for a
period of 10 hours. All of the measurements were measured
in the temperature- and humidity-controlled room with
temperature of 25◦C and humidity of 60%.
This study was approved by the Ethical Committee on
Research Involving Human Subjects, Faculty of Medicine,
Siriraj Hospital, Mahidol University, and conformed to the
guidelines of the 1975 Declaration of Helsinki. Written in-
formed consent was obtained from all study subjects.
2.1. Statistical Analysis. Unpaired t-test was employed to
compare baseline values for hydration and elasticity between
the study and control groups. Paired t-test was used to com-
pare baseline hydration and elasticity to those obtained after
the 4-week cream trial period. Repeated analysis of Variance
(ANOVA) test was used to compare skin hydration between
both volar forearms of each subjects at baseline, immediately
after application, and every 1 hour after application for a
period of 10 hours. Bonferroni posttest was also used to
compare skin hydration between each of the time intervals.
All statistical analyses were performed using SPSS software,
version 16.0.
3. Results
For the ﬁrst part of the study, ﬁfty seven of the original
sixty volunteers (29MPS, 28 control; mean age 36 years inDermatology Research and Practice 3
both groups) completed the 4 weeks of the study protocol.
The average baseline values of skin hydration in MPS and
vehicle-control group were 49.04 (±5.80) and 47.86 (±6.74)
(P = 0.47). The average baseline value of skin elasticity (R5)
in MPS and vehicle-control group were 54.24 (±8.28) and
54.95 (±9.26)(P = 0.76).
Statistical analysis of skin hydration values as measured
by the corneometer at baseline and after the 4-week study
period a statistically signiﬁcant improvement in hydration
among both groups (Figures 1(a) and 1(b)). Additionally, a
statistically signiﬁcant diﬀerence in the degree of improve-
mentinhydrationwasfoundwhencomparingtheamountof
increase in hydration between the control and study groups
(P = 0.01).
Although the Cutometer at reading demonstrated a
statisticallysigniﬁcantimprovementinelasticityamongboth
groups after the 4-week period (Figure 2), no statistically
signiﬁcant diﬀerence in the degree of improvement in
elasticity was found between the control and study groups
(P = 0.15).
None of the volunteers reported any adverse reactions to
either the control or study treatment throughout the study
period.
Forthesecondpartofthestudy,all20subjectscompleted
the10hoursofthestudyprotocol.Statisticalanalysisveriﬁed
that patient age, room temperature, and air humidity did
not diﬀer signiﬁcantly during 10 hours of study period. The
mean age of subjects were 33.0 years (SD = 2.71). The
room temperature and the air humidity were set at 24.33◦C
(SD = 0.42) and 60.82% (SD = 1.97), respectively. The
average baseline values of skin hydration in MPS and control
side were 41.87 (SD = 6.71) and 40.68 (SD = 7.67),
respectively. Statistical analysis of skin hydration values as
measured by the corneometer demonstrated that there was
no signiﬁcantly diﬀerences in skin hydration between the
MPS and control side before treatment (P = 0.61). However,
skin hydration of the MPS side improved signiﬁcantly
immediately after application, and this improvement was
maintained for 10 hours after single application (P<0.01)
(Figure 3). None of the volunteers reported any adverse
reactions to MPS throughout the study period.
4. Discussion
Mucopolysaccharidepolysulphate in MPS cream is similar to
the body’s own mucopolysaccharides. The pharmacological
properties of topically applied MPS correlate well with the
documented clinical eﬀects[15]. Inthe ﬁrst part of the study,
we demonstrated that MPS application twice daily over a 4-
week period resulted in a signiﬁcant improvement in skin
hydration, compared to similar application of control cream
base. Our ﬁndings may be explained by taking into consid-
eration the chemical structure of MPS, a glycosaminoglycans
(GAGs)derivative,whichhasabundanthydroxylgroups,and
readily form hydrogen bonds with adjacent water molecules.
The association of water with MPS molecules prevents
evaporation of water, resulting in decreased desiccation of
the surrounding skin.
The ﬁnding that consistent MPS application improves
skin hydration is an important ﬁnding as diminished skin
hydration is associated with numerous skin conditions,
including cutaneous photoaging and xerosis. Cutaneous
photoaging correlates with focal deposition of GAGs within
the mid- and deep dermis as compared to the diﬀuse
distribution of GAGs found in healthy sun-protected der-
mis, in which these macromolecules are found through
the dermis between collagen bundles [7]. Although sun-
damaged skin contains increased amounts of glycosamino-
glycans, given alterations in elastotic materials, these
molecules may not be able to function in the typical
mechanism as that of sun-protected skin. As a type of
glycosaminoglycan, topical MPS application may provide
a more even distribution of GAGs, similar to that of
healthy non-UV-damaged dermis. These evenly distributed
GAGs may then serve to promote hydration and aid
in the movement of nutrients and cellular metabolites
[16].
Xerosis, characterized clinically by pruritic, dry, cracked,
and ﬁssured skin with scaling, is increasingly common
among the elderly because aged individuals have decreased
sebaceous and sweat gland activity [16] .T h ec r a c k sa n dﬁ s -
sures that characterize this condition result from epidermal
water loss, and therefore this condition may be improved
with the use of MPS.
Dermal absorption of MPS in human was investigated
in vitro. The results demonstrated that MPS penetrated
the skin and was able to reach dermal layers in eﬀective
concentrations [17]. However, the absorption of MPS to
the systemic circulation was too low to inﬂuence blood
coagulation [18, 19]. This could be interpreted that MPS
may be “trapped” in dermis leading to increased epider-
mal water retention. Since MPS includes organohepari-
noid compound, hyaluronic acid, glycosaminoglycans, and
so forth. Hydration of the skin might be improved by
the increasing of hyaluronic acid and glycosaminoglycans
contents.
Notably, there was statistically signiﬁcant improvement
in elasticity among both groups when comparing baseline
to after the 4-week period of application of either the
cream base or the MPS-containing cream. However, MPS
application did not result in signiﬁcant improvement in skin
elasticity compared to the control cream base, indicating
that the physiologic aﬀect of MPS on skin does not involve
an increase in collagen production signiﬁcant enough to
resultinaclinicallydetectableimprovementinskinelasticity.
Therefore, the other ingredients in vehicle cream base, for
example, glycerin [20] and liquid paraﬃn[ 21], may be
responsible for the improvement of skin elasticity in both
groups.
In the second part of this study, we demonstrated that
singleMPSapplicationresultedinasigniﬁcantimprovement
in skin hydration for at least 10 consecutive hours, compared
to similar application of control cream base. The results
of this study indicated that MPS may serve as a beneﬁcial
therapy in the treatment of xerosis the ﬁnding that MPS
aﬀected may be explained by taking into consideration
the chemical structure of MPS. MPS, a glycosaminoglycans4 Dermatology Research and Practice
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Figure 1: 32.1% of vehicle-control subjects (a) and 58.6% of MPS subjects (b) demonstrated improvement to normal skin hydration after 4
weeks of application (P<0.01).
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(GAGs) derivative, has abundant hydroxyl groups, which
readily form hydrogen bonds with adjacent water molecules
[16]. The association of water with MPS molecules prevents
evaporation of water, resulting in decreased desiccation of
the surrounding skin.
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Figure 3: Skin hydration at MPS side was maintained for 10 hours
after single application.
5. Conclusions
In summary, this study demonstrated that MPS provided
improvement of skin hydration but not skin elasticity in
woman with dry skin, compared with vehicle control. MPS
could also improve the hydration human skin for at least 10
hours after single application. Future study considerationsDermatology Research and Practice 5
should include evaluating the eﬀect of MPS on speciﬁc xe-
rotic skin conditions as well as determining optimal MPS
concentrations for the treatment of such a condition.
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